CG Oncology Hits New 12-Month High

Is Now the Time to Buy This Biotech Stock?

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Shares of CG Oncology, Inc. (NASDAQ:CGON) reached a new 52-week high on Wednesday, trading as high as $60.69 per share. The clinical-stage biopharmaceutical company focused on antibody-based cancer immunotherapies has seen its stock price surge in recent months as analysts have become increasingly bullish on its prospects.

Why it matters

CG Oncology's stock price jump reflects growing investor optimism about the company's pipeline of experimental cancer treatments. As a clinical-stage biotech, CG Oncology's future success will depend on the performance of its drug candidates in clinical trials, making the stock a higher-risk, higher-potential investment opportunity.

The details

Several Wall Street analysts have raised their price targets on CG Oncology in recent months, with Truist Financial, Wedbush, Piper Sandler, and The Goldman Sachs Group all issuing "buy" ratings and increased price targets ranging from $66 to $82 per share. The analysts cited CG Oncology's promising pipeline and early clinical data as reasons for their bullish outlooks.

  • CG Oncology's stock hit a new 52-week high of $60.69 per share on Wednesday, March 4, 2026.
  • The company reported its latest quarterly earnings on Friday, February 27, 2026.

The players

CG Oncology, Inc.

A clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

CG Oncology's stock surge reflects growing investor optimism about the company's pipeline of experimental cancer treatments, but as a clinical-stage biotech, its future success will depend heavily on the performance of its drug candidates in clinical trials, making it a higher-risk, higher-potential investment opportunity.